NEW YORK (GenomeWeb) – Several equity research today initiated coverage of Guardant Health with favorable ratings, citing the firm's strong liquid biopsy testing portfolio — and especially its Guardant360 assay — as reasons for their optimism.
To read the full story....
Register for Free....and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.